LEADERS FREE 2
Brief summary
To demonstrate that the BioFreedomTM Drug Coated Stent is non-inferior to the Gazelle™ BMS arm of the Leaders Free study in high bleeding risk patients treated with one month DAPT only
Primary endpoints
- Safety:
The composite of cardiac death and myocardial infarction at 1 year
- Efficacy:
The incidence of clinically driven target lesion revascularization at 1 year
CERC Services
- CEC
- Monitoring
- Core Laboratory
- Regulatory
Countries
85 sites in total distributed throughout Europe and North America (US and Canada). CERC is responsible for the European sites. These are distributed by 5 countries: France, Denmark, Germany, UK and Italy.
Centers number
16 centers managed by CERC.
Latest News
EuroPCR 2017: Two-year follow-up of LEADERS FREE ACS: is there a place left for BMS in ACS?